Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Comparison: Tesamorelin Delivery Routes

Subcutaneous Injection ~100% (relative to IV) Direct absorption into capillary beds; bypasses GI tract and first-pass metabolism Standard route in all clinical trials; 2mg daily dosing Requires reconstitution and sterile injection technique Oral Administration

This comparison does not assign a generated winner or score.

  • Subcutaneous Injection
  • ~100% (relative to IV)
  • Direct absorption into capillary beds; bypasses GI tract and first-pass metabolism
  • Standard route in all clinical trials; 2mg daily dosing
  • Requires reconstitution and sterile injection technique
  • Oral Administration
  • <1% (effectively zero)
  • Peptide must survive gastric acid (pH 1.5–3.5), resist proteolytic cleavage by pepsin/trypsin, and cross intestinal epithelium
  • Not used—no validated formulation exists
  • Peptide degradation occurs within 15–20 minutes of ingestion
  • Intranasal Delivery
  • 5–10% (experimental)
  • Absorption across nasal mucosa; avoids first-pass metabolism
  • Not FDA-approved for tesamorelin; limited clinical data
  • Requires permeation enhancers; variable absorption due to mucosal clearance
  • Buccal/Sublingual
  • 3–8% (theoretical)
  • Absorption through oral mucosa into systemic circulation
  • Not validated for tesamorelin; used for some small peptides
  • Rapid salivary clearance; peptide must resist oral proteases
  • Professional Assessment
  • Subcutaneous injection is the only clinically proven route. Oral, intranasal, and buccal routes fail due to peptide instability and insufficient absorption. Any product claiming oral tesamorelin efficacy is either misrepresenting the formulation or selling a non-therapeutic compound.